Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biotronik, Clearpoint Neuro, Cortec, Efferon, Regeneron, Sanofi, Specialised.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbvie, Adbiotech, Alpharose, Apotex, Cumberland, Day One, Definium, Dogwood, Exicure, Healthcare Royalty, J&J, Lift, Oncoceutics, Pridcor, Servier, Silo, Smart Nanovirus, Viz.ai.
Clinical updates for biopharma and med tech, including data readouts and publications: Biotia, George Medicines, Kallyope, LB, Mozart, Nectero, Neurocrine, Novo Nordisk, Xvivo.
New hires and promotions in the biopharma and med-tech industries, including: Amgen, Corvus, Ena Respiratory, Epitopea, Helus, Inventiva, Liquidcell, Madrigal, Protagenic, Santhera, Signum, Theialife, Vanda.
BioWorld tracked 209 clinical trial readouts across phases I through III in March 2026, up from 152 in February and 144 in January. Among late-stage programs, 26 phase III trials reported positive results, two produced mixed results, and three failed to meet key endpoints. By phase, March updates included 62 from phase I, 74 from phase II and 73 phase III.
Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.
Anaptysbio Inc. announced in September of 2025 that it planned to separate its drug development business from the royalties it receives on Jemperli (dostarlimab) from GSK plc and imsidolimab from Vanda Pharmaceuticals Inc. Just seven months later, on April 20, 2026, well ahead of its “year-end 2026” goal, First Tracks Biotherapeutics Inc., the drug development arm of the company, started trading as a standalone company on Nasdaq under the ticker symbol TRAX.
Edwards Lifesciences Corp. raised its full-year 2026 guidance after seeing strong sales in the first quarter, particulalry from its transcatheter aortic valve replacement (TAVR) business. The company now expects sales growth of 9% to 11%, up from prior outlook of 8% to 10%, and adjusted earnings per share of $2.95 to $3.05, compared with earlier guidance of $2.90 to $3.05.
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything from epilepsy and narcolepsy to post-traumatic stress disorder and hyperphagia.
RSS
